The inflammatory cytokines, such as TNF-α, IL-6, and IL-1β, and the transcription pathways related to them [30, 31], especially NF-κB and STATs, are considered as potential targets for anti-CRC therapy [11, 13, 32–36]. This evidence concerns the gene IL1B and colorectal carcinoma.